Large study finds Novavax COVID-19 shot around 90% efficiency – –

0
5
Large study finds Novavax COVID-19 shot around 90% efficiency – –


Vaccine maker Novavax said on Monday that its vaccine was highly effective against COVID-19 and also protected against variants in a large late-stage study in the United States and Mexico.

The vaccine was around 90% effective overall and preliminary data showed it to be safe, the company said.

While the demand for COVID-19 vaccines in the United States has declined dramatically, the need for more vaccines around the world remains critical. The Novavax vaccine, which is easy to store and transport, is expected to play an important role in increasing vaccine supply in developing countries.

That help is still months away, however. The company said it plans to seek authorization for injections in the United States, Europe and elsewhere by the end of September and would be able to produce up to 100 million doses per month by then.

“A lot of our first doses will go to low- and middle-income countries, and that was the goal initially,” Novavax chief executive Stanley Erck told The Associated Press.

While more than half of the American population has received at least one dose of the COVID-19 vaccine, less than 1% of people in the developing world have received a single injection, according to Our World In Data.

The Novavax study involved nearly 30,000 people aged 18 and over in the United States and Mexico. Two-thirds received two doses of the vaccine, three weeks apart, and the rest received sham injections.

There were 77 cases of COVID-19 – 14 in the group that received the vaccine and the rest in volunteers who received sham injections. None in the vaccine group had moderate or severe disease, compared to 14 in the placebo group.

The vaccine was also effective against several variants, including the one first detected in the UK which is dominant in the US, and in high-risk populations including the elderly and people with other health conditions. .

The side effects were mostly mild – tenderness and pain at the injection site. There have been no reports of blood clots or unusual heart problems, Erck said.

Novavax announced the results in a press release and plans to publish them in a medical journal, where they will be reviewed by independent experts. The Maryland-based company previously published the results of smaller studies conducted in Britain and South Africa.

COVID-19 vaccines train the body to recognize the coronavirus, especially the spike protein that covers it, and prepare to fight the virus. The Novavax vaccine is made from laboratory-grown copies of this protein. It’s different from some of the other now widely used vaccines, which include genetic instructions for the body to make its own spike protein.

Novavax vaccine can be stored in standard refrigerators, which makes it easier to distribute.

Novavax previously announced manufacturing delays due to supply shortages. The company now plans to achieve production of 100 million doses per month by the end of September and 150 million doses per month by December.

The company has committed to deliver 110 million doses to the United States over the next year and a total of 1.1 billion doses to developing countries.

In May, the Gavi vaccine alliance announced it had signed an agreement to purchase 350 million doses of Novavax vaccine, with deliveries scheduled to begin in the third quarter. COVAX, the global initiative to deliver vaccines to countries, faces a severe vaccine shortage after its largest supplier in India suspended exports until the end of the year,

Novavax has been working on vaccine development for more than three decades, but has not brought one to the market. The company’s work on the coronavirus vaccine is partially funded by the US government.

——

AP Medical Writer Maria Cheng contributed to this report.

——

The Associated Press’s Department of Health and Science receives support from the Department of Science Education at Howard Hughes Medical Institute. The AP is solely responsible for all content.

LEAVE A REPLY

Please enter your comment!
Please enter your name here